Lincoln Pharmaceuticals Limited (BOM:531633)
India · Delayed Price · Currency is INR 622.10
+9.25 (1.51%)
At close: Aug 17, 2026
Lincoln Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 12,275 | 11,304 | 11,047 | 11,725 | 6,784 | 6,230 | |
Market Cap Growth | 12.85% | 2.32% | -5.78% | 72.84% | 8.89% | 38.64% |
Enterprise Value | 9,907 | 8,985 | 9,087 | 10,027 | 5,679 | 5,224 |
Last Close Price | 612.85 | 564.35 | 549.78 | 582.16 | 335.85 | 306.89 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 12.73 | 12.86 | 13.42 | 12.57 | 9.31 | 8.98 |
Forward PE | - | 7.52 | 7.52 | 7.52 | 7.52 | 7.52 |
PS Ratio | 1.75 | 1.69 | 1.77 | 2.02 | 1.33 | 1.32 |
PB Ratio | 1.62 | 1.49 | 1.65 | 1.98 | 1.35 | 1.44 |
P/TBV Ratio | 1.62 | 1.49 | 1.65 | 1.98 | 1.35 | 1.44 |
P/FCF Ratio | 15.17 | 13.97 | 14.93 | 49.39 | 27.13 | 20.36 |
P/OCF Ratio | 11.54 | 10.63 | 11.88 | 18.55 | 17.28 | 8.18 |
PEG Ratio | - | 0.47 | 0.47 | 0.47 | 0.47 | 0.47 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.41 | 1.34 | 1.46 | 1.73 | 1.11 | 1.11 |
EV/EBITDA Ratio | 8.98 | 9.20 | 8.92 | 10.02 | 6.34 | 5.46 |
EV/EBIT Ratio | 10.39 | 10.80 | 10.20 | 11.19 | 7.05 | 5.96 |
EV/FCF Ratio | 12.24 | 11.10 | 12.28 | 42.23 | 22.71 | 17.07 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.01 | 0.01 | - | 0.00 | 0.00 | 0.01 |
Debt / EBITDA Ratio | 0.05 | 0.05 | - | 0.01 | 0.02 | 0.02 |
Debt / FCF Ratio | 0.06 | 0.06 | - | 0.05 | 0.08 | 0.07 |
Net Debt / Equity Ratio | -0.31 | -0.31 | -0.29 | -0.25 | -0.21 | -0.26 |
Net Debt / EBITDA Ratio | -2.42 | -2.42 | -1.92 | -1.51 | -1.18 | -1.18 |
Net Debt / FCF Ratio | -2.93 | -2.93 | -2.64 | -6.38 | -4.24 | -3.69 |
Asset Turnover | 0.80 | 0.80 | 0.83 | 0.90 | 0.91 | 0.96 |
Inventory Turnover | 3.92 | 3.92 | 3.81 | 3.85 | 3.44 | 3.72 |
Quick Ratio | 3.63 | 3.63 | 3.41 | 3.41 | 3.39 | 2.56 |
Current Ratio | 5.25 | 5.25 | 4.71 | 4.74 | 5.09 | 3.90 |
Return on Equity (ROE) | 12.30% | 12.30% | 13.02% | 17.04% | 15.59% | 17.36% |
Return on Assets (ROA) | 6.16% | 6.16% | 7.43% | 8.70% | 8.97% | 11.11% |
Return on Invested Capital (ROIC) | 12.59% | 12.69% | 14.64% | 16.32% | 16.32% | 21.41% |
Return on Capital Employed (ROCE) | 10.70% | 10.70% | 12.90% | 14.70% | 15.60% | 19.80% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 7.86% | 7.78% | 7.45% | 7.96% | 10.75% | 11.13% |
FCF Yield | 6.59% | 7.16% | 6.70% | 2.02% | 3.69% | 4.91% |
Dividend Yield | 0.29% | 0.32% | 0.33% | 0.31% | 0.45% | 0.49% |
Payout Ratio | - | 4.10% | 4.38% | 3.22% | 4.12% | 4.33% |
Buyback Yield / Dilution | -0.00% | -0.00% | - | - | - | - |
Total Shareholder Return | 0.29% | 0.32% | 0.33% | 0.31% | 0.45% | 0.49% |